**Name of Journal: *World Journal of Gastrointestinal Oncology***

**Manuscript NO: 46385**

**Manuscript Type: ORIGINAL ARTICLE**

***Basic Study***

***SFRP4* expression correlates with epithelial mesenchymal transition-linked genes and poor overall survival in colon cancer patients**

Nfonsam LE *et al*. *SFRP4* overexpression associates with poor survival

**Landry E Nfonsam, Jana Jandova, Hunter C Jecius, Pamela N Omesiete, Valentine N Nfonsam**

**Landry E Nfonsam,** Department of Genetics, Children’s Hospital of Eastern Ontario, Ottawa, Ontario K1H 8L1, Canada

**Jana Jandova, Hunter C Jecius, Pamela N Omesiete, Valentine N Nfonsam,** Department of Surgery, University of Arizona, Tucson, AZ 85724, United States

**ORCID number:** Landry E Nfonsam (0000-0002-5715-2545); Jana Jandova (0000-0002-9100-9574); Hunter C Jecius (0000-0002-6415-1436); Pamela N Omesiete (0000-0001-6824-1853); Valentine N Nfonsam (0000-0002-1213-8053).

**Author contributions:** Nfonsam LE and Jandova J contributed equally to this work; Nfonsam LE, Jandova J, and Nfonsam VN designed the research; Nfonsam LE, Jandova J, Jecius HC, and Omesiete PN performed the research; Nfonsam LE and Jandova J analyzed and interpreted data; Nfonsam LE, Jandova J, Jecius HC, Omesiete PN, and Nfonsam VN wrote the paper.

**Supported by** the SAGES research grant (to Nfonsam VN).

**Institutional review board statement:** This study does not involve human subjects. It utilizes the publicly available de-identified colon adenocarcinoma data set from The Cancer Genome Atlas.

**Conflict-of-interest statement:** All authors declare no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Valentine N Nfonsam, MD, Associate Professor,** Department of Surgery, University of Arizona, 1501 N Campbell Avenue, Tucson, AZ 85724, United States. vnfonsam@surgery.arizona.edu

**Received:** February 14, 2019

**Peer-review started:** February 15, 2019

**First decision:** March 14, 2019

**Revised:** April 2, 2019

**Accepted:** May 23, 2019

**Article in press:** May 23, 2019

**Published online:** August 15, 2019

**Abstract**

***BACKGROUND***

Colon cancer is among the most commonly diagnosed cancers in the United States with an estimated 97220 new cases expected by the end of 2018. It affects 1.2 million people around the world and is responsible for about 0.6 million deaths every year. Despite decline in overall incidence and mortality over the past 30 years, there continues to be an alarming rise in early-onset colon cancer cases (< 50 years). Patients are often diagnosed at late stages of the disease and tend to have poor survival. We previously showed that the *WNT* “gatekeeper” gene, secreted frizzled-related protein 4 (*SFRP4*), is over-expressed in early-onset colon cancer. *SFRP4* is speculated to play an essential role in cancer by inhibiting the epithelial mesenchymal transition (EMT).

***AIM***

To investigate the correlation between *SFRP4* expression and EMT-linked genes in colon cancer and how it affects patient survival.

***METHODS***

*SFRP4* expression relative to that of EMT-linked genes and survival analysis were performed using the University of California Santa Cruz Cancer Browser interface.

***RESULTS***

*SFRP4* was found to be co-expressed with the EMT-linked markers *CDH2*, *FN1*, *VIM*, *TWIST1*, *TWIST2*, *SNAI1*, *SNAI2*, *ZEB1*, *ZEB2*, *POSTN*, *MMP2*, *MMP7*, *MMP9*, and *COL1A1*. *SFRP4* expression negatively correlated with the EMT-linked suppressors *CLDN4*, *CLDN7*, *TJP3*, *MUC1*, and *CDH1*. The expression of *SFRP4* and the EMT-linked markers was higher in mesenchymal-like samples compared to epithelial-like samples which potentially implicates *SFRP4-*EMT mechanism in colon cancer. Additionally, patients overexpressing *SFRP4* presented with poor overall survival (*P* = 0.0293).

***CONCLUSION***

Considering the implication of *SFRP4* in early-onset colon cancer, particularly in the context of EMT, tumor metastasis, and invasion, and the effect of increased expression on colon cancer patient survival, *SFRP4* might be a potential biomarker for early-onset colon cancer that could be targeted for diagnosis and/or disease therapy.

**Key words:** Secreted frizzled-related protein 4; Epithelial mesenchymal transition; Colon cancer; Survival

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We have previously shown that secreted frizzled-related protein 4 (*SFRP4*) is over-expressed in colon cancer, especially in patients younger than 50 years. As these early-onset colon cancers tend to be more aggressive and negatively affecting patients’ survival, we sought to evaluate whether *SFRP4* is co-expressed with epithelial-mesenchymal transition-linked genes that play key roles in cancer progression. Our results using a large colon adenocarcinoma-The Cancer Genome Atlas cohort revealed that *SFRP4* is over-expressed in colon cancer patients together with epithelial-mesenchymal transition-linked genes. Moreover, colon cancer patients with high expression levels of *SFRP4* showed significantly poorer survival relative to colon cancer patients with lower *SFRP4* expression.

**Citation:** Nfonsam LE, Jandova J, Jecius HC, Omesiete PN, Nfonsam VN. *SFRP4* expression correlates with epithelial mesenchymal transition-linked genes and poor overall survival in colon cancer patients. *World J Gastrointest Oncol* 2019; 11(8): 589-598

**URL:** https://www.wjgnet.com/1948-5204/full/v11/i8/589.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v11.i8.589

**INTRODUCTION**

Colon cancer is an important contributor to worldwide cancer morbidity and mortality, affecting an estimated 1.2 million individuals and responsible for 0.6 million deaths every year[1]. In the United States, colon cancer is among the most commonly diagnosed cancer with an estimated 97220 new cases expected by the end of 2018 and an overall life time risk of about 4.49% for men and 4.15% for women[2,3]. Despite the decline in overall incidence and mortality of colon cancer over the past 30 years[4], there continues to be an alarming rise in the number of early-onset colon cancer cases in individuals younger than 50 years[5]. Using the Surveillance Epidemiology and End Results Program Cancer Registries database, we previously demonstrated that this rise is most significant within the age group 40-44[6]. About 70%-80% of early-onset colon cancer cases are sporadic, and these patients have aggressive features, are often diagnosed at a more advanced stage, and tend to have poor survival[5-11].

In 2016, we showed that the secreted frizzled-related protein 4 (*SFRP4*) gene was uniquely over-expressed in early-onset colon cancer patients[12]. This is a protein coding gene and a member of the *SFRP* family. The cysteine-rich domain of *SFRP4* is homologous to the putative *WNT*-binding site of frizzled proteins, making *SFRP4*, like other *SFRP*s, a modulator of *WNT* signaling[13,14]. As a *WNT* inhibitor, *SFRP4* prevents cell growth and proliferation and has been implicated in Pyle disease[15]. *SFRP4* is expressed in mouse embryonic mesenchyme, cardiovascular system, and musculoskeletal system[16]. Reports show that *SFRP4* plays an essential role in ovarian cancer pathogenicity by inhibiting epithelial-mesenchymal transition (EMT) and cell migration, while promoting cell adhesion[13].

Although EMT is a typical process in embryonic development, heart valve formation, and other developmental processes, its role in promoting cancer metastasis is well documented[17,18]. EMT provides a molecular environment that allows epithelial cells to lose polarity and cell-to-cell adhesion and gain migratory and invasive properties to become mesenchymal cells[17,18]. The relationship between *SFRP4* and EMT-linked genes in colon cancer pathogenesis and the implication of *SFRP4* overexpression in patient survival has not been investigated previously. In this study, we demonstrate a correlation between *SFRP4* gene expression and the expression of some key EMT-linked genes in colon cancer and show that the overexpression of *SFRP4* associates with poor survival in colon cancer patients.

**MATERIALS AND METHODS**

***Ethics statement***

This study does not involve human subjects. It utilizes the publicly available de-identified colon adenocarcinoma (COAD) data set from The Cancer Genome Atlas (TCGA).

***TCGA program***

A landmark cancer genomics program molecularly characterized over 20000 primary cancer and matched normal samples spanning 33 cancer types. TCGA was formed in 2005 when the U.S. National Cancer and National Human Genome Research Institutes teamed together to support the launch of the project to map comprehensively various cancer genomic changes (<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/history/timeline>). This joint effort brought together researchers from diverse disciplines and multiple institutions. Over the next dozen years, TCGA generated over 2.5 petabytes of genomic, epigenomic, transcriptomic, and proteomic data. The data, which has already led to improvements in our ability to diagnose, treat, and prevent cancer, will remain publicly available for anyone in the research community to use (<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>).

As of March 2019, the TCGA data portal contains 365463 pieces of genomic and clinical data for 45 projects; 68 primary sites; 33549 cases; 22872 genes, and 3142246 mutations. The TCGA-COAD project contains 461 cases including two primary sites, colon and rectosigmoid junction, and the following disease types: adenomas and adenocarcinomas, complex epithelial neoplasms; cystic, mucinous, and serous neoplasms, epithelial neoplasms, and no other specified carcinomas.

***Data set***

A total of 286 of 462 “Primary Tumor” samples from TCGA-COAD cohort was used in this study for gene expression and Kaplan-Meier survival analyses[19]. Table 1 summarizes the gender, age, and tumor stage of samples.

***Gene expression***

*SFRP4* gene expression relative to the EMT genes, Fibronectin (*FN1*), Vimentin (*VIM*),Zinc Finger E-Box Binding Homeobox 1 (*ZEB1*), *ZEB2*, Twist Family BHLH Transcription Factor 1 (*TWIST1*), *TWIST2*, Snail Family Transcriptional Repressor 1 (*SNAI1*), *SNAI2*, N-cadherin (*CDH2*), Claudin 4 (*CLDN4*), *CLDN7*, Tight Junction Protein 3 (*TJP3*), Mucin 1 (*MUC1*), and E-Cadherin (*CDH1*), was performed using the TCGA-COAD dataset as previously described[20]. Pearson’s and Spearman’s rank coefficients and two-dimensional correlation scatter plots were generated using the University of California Santa Cruz Cancer Browser Interface (<https://xenabrowser.net>)[21].

***Survival analysis***

The TCGA-COAD “Primary tumor” dataset was used to perform and visualize Kaplan-Meier overall survival analysis using the University of California Santa Cruz Xena Browser for cancer genomics (<https://xenabrowser.net/datapages/?Cohort-TCGA%20Colon%20Cancer%20(COAD)>)[22,23]. *P* values were obtained using the Kaplan-Meier Estimator.

**RESULTS**

***Co-expression of SFRP4 with EMT genes***

The role of *SFRP4* in epithelial-mesenchymal transition was investigated in colon cancer by comparing its expression to that of some key EMT-linked genes using 286 colon cancer patients. We observed co-expression and a positive correlation by Pearson’s and Spearman’s rank coefficient analysis of *SFRP4* with the EMT markers *CDH2*, *FN1*, *VIM*, *ZEB1*, *ZEB2*, *TWIST1*, *TWIST2*, *SNAI1*, *SNAI2*, Periostin (*POSTN*), Matrix Metallopeptidase 2 (*MMP2*), *MMP9*, *MMP7*, and Collagen 1 (*COL1A1*) (Figure 1 and Figure 2). A higher expression of *SFRP4* and the EMT-linked markers was observed in samples that were more mesenchymal than epithelial. A negative correlation was observed between *SFRP4* and *CLDN4*, *CLDN7*, *TJP3*, *MUC1*, and *CDH1* (Figure 1 and Figure 3). Based on the Pearson’s and Spearman’s rank coefficients, *SFRP4* shows the strongest correlation with *CDH2* followed by *MMP2*, and the least correlation with *CLDN7* (Figure 2 and Figure 3). These data suggest a role for *SFRP4* in the EMT molecular pathway.

***Colon cancer patients over-expressing SFRP4 have poor overall survival***

We analyzed the effect of *SFRP4* overexpression on colon cancer patient survival. Our data showed that colon cancer patients with higher *SFRP4* expression (≥ 8.661) had poor overall survival compared to patients with lower *SFRP4* expression (< 8.661) (Figure 4A). A similar trend was observed when patient cohort was divided into three groups. Patients with intermediate levels of *SFRP4* expression (7.467-10.05) showed survival curve that was between that of patients with higher (≥ 10.05) and lower (< 7.467) expression (Figure 4B). These data demonstrate that *SFRP4* has an impact on colon cancer patient survival.

**DISCUSSION**

Very little is known about the role of *SFRP4* in cancer pathogenesis, let alone its mechanism of action. Most of the speculations on *SFRP4* mechanism appear to focus on its role as a *WNT* signaling modulator, through which it suppresses epithelial mesenchymal transition, a mechanism that is implicated in cancer metastasis and invasion[13,17,18]. In ovarian cancer, *SFRP4* regulates metastasis by inhibiting EMT-linked genes, cell proliferation, and migration, while promoting apoptosis and upregulating cell adhesion molecules such as *CDH1*[13,24]. A Study by Muley *et al*[25] showed that *SFRP4* can restrict ovarian serous cystadenocarcinoma growth in mice by interfering with endothelial cell function, suggesting *SFRP4* as a potent angiogenesis inhibitor. While these observations indicate that *SFRP4* represses cancer pathogenesis, this is in contrast to our previous observation of *SFRP4* upregulation in early-onset colon cancer[12] or its strong correlation with epithelial mesenchymal-linked genes observed in this study.

Our previous report on the overexpression of *SFRP4* in early-onset colon cancer informed us of the potential role of *SFRP4* in colon cancer particularly with respect to age of onset[12]. Our data showed that *SFRP4* co-expresses and correlates positively with the EMT-linked genes *CDH2*, *FN1*, *VIM*, *SNAI1*, *SNAI2*, *ZEB1*, *ZEB2*, *TWIST1*, *POSTN*, *COL1A1*, *MMP2*, *MMP7*, and *MMP9*, many of which promote epithelial mesenchymal transition by repressing proteins that maintain tissue integrity such as *CDH1*[26,27]. Some of the hallmarks of EMT are cell separation and invasion, characterized by loss of cell-cell adhesion and gain of migratory and invasive properties[18]. Given the role of *SFRP4* as an EMT inhibitor, overexpression in early-onset colon cancer might be a response mechanism to serve as a check on EMT in the wake of increase expression of EMT genes.

However, overexpression of *SFRP4* may not always correlate with EMT suppression. There is accumulating evidence that *SFRP* family proteins may also have oncogenic potential in certain cancer types[28,29]. While the binding and sequestering of *WNT* ligand by *SFRP*s inhibit *WNT* signaling[30-33], binding may also allow *SFRP*s to act as carriers for *WNT* proteins in a diffusion gradient, thus expanding the range and activity of *WNT* signaling. This has been reported in *Xenopus* where *SFRP3* and *Crescent* were shown potentially to activate canonical *WNT* signaling by promoting the diffusion of *WNT8* and *WNT11*[34]. There have also been reports on the dimerization of the N-terminal cysteine-rich domain of *SFRP*s and Frizzled proteins, hence suggesting *SFRP*s direct activation of *WNT* signaling by mimicking the *WNT* ligand[35-37]. Additionally, it has been suggested that by antagonizing each other, the *SFRPs* indirectly activate *WNT* signaling, as seen in rat renal organogenesis where *SFRP2* was reported to inhibit *SFRP1* activities[38]. Also, studies have shown that *WNT* regulation could be concentration dependent with low *SFRP* concentrations activating *WNT* signaling and high concentrations inhibiting it[39].

Consistent with the concept of *SFRPs* functioning as oncogenes, *SFRP1* has been reported to be over-expressed in basal-like breast cancers and implicated in brain-specific metastases, while *SFRP2* induces mammary tumor formation in canines by blocking apoptosis[40,41]. Both *SFRP1* and *SFRP2* promote cellular invasion, proliferation, and *in vivo* tumor growth in renal cancer[42,43], and *SFRP1* in gastric cancer. *SFRP2* enhances *WNT3A* signaling in HEK293 and HSG cells[44] and activates *WNT* signaling through direct interaction with *FZ4/7* in the mouse[45]. Interestingly, overexpression of *SFRP4* has also been observed in stomach cancer where it associates with poor patient outcomes and interacts strongly with EMT-linked genes in gliomas[29]. Taken together, these observations suggest that besides being a *WNT* signaling inhibitor, the *SFRP* family members, including *SFRP4*, also have oncogenic potentials, and their mechanism of action might be context dependent or cancer type dependent.

Consistent with the important role *MMP2* plays in the breakdown of the extracellular matrix and the EMT process, particularly in cell invasion and metastasis, *SFRP4* expression was strongly correlated with *MMP2* . In addition to *CDH1*, *SFRP4* was negatively correlated with many other cell adhesion molecules. Given the role these genes play as gatekeepers of EMT and metastasis, it follows that *SFRP4* is upregulated with EMT following downregulation of cell-adhesion molecules. Overexpression of *SFRP4* is also consistent with overexpression of other EMT regulators we previously reported in early-onset colon cancer, such as cartilage oligomeric matrix protein, (*COMP*) which catalyzes collagen fibrillation to maintain the extracellular matrix[20,46].

Overexpression of *SFRP4* in colon cancer patients resulted in poor survival that correlated with the survival analysis observed for colon cancer patients overexpressing *COMP*[20]. Given the implication of *WNT* signaling in many developmental and disease pathways[47-49] and the knowledge that *SFRP4* inhibits *WNT* signaling, it is possible that early deaths might be due to secondary complications following overexpression of *SFRP4*, which interferes with the normal functions of neighboring healthy cells. However, it is also possible that early deaths are due primarily to disease independent of *SFRP4*, whose overexpression might only be a consequence of the disease.

Although high *SFRP* expression in colon cancer was observed in this study, others have suggested that *SFPR4* expression in tumor may be contributed by the stroma fraction. This was documented in studies by Vincent *et al*[29] where a strong correlation between *SFRP4* and the stroma was observed in 14 cancer types, including colorectal. Nevertheless, considering that the stroma constitutes an integral part of the tumor microenvironment, its expression of *SFRP4* will undoubtedly constitute an important disease mechanism for potential targeted therapy.

In summary, we had previous shown that *SFRP4* was over-expressed in early-onset colon cancer[12] and report here *SFRP4* expression was correlated with EMT-linked genes. These findings highlight *SFRP4* as an important contributor to the pathogenesis of colon cancer, particularly early-onset colon cancer, and therefore as a potential biomarker for the early diagnosis of colon cancer. Considering that *SFRP4* modulates *WNT* signaling during cell proliferation, migration, and EMT, which are all hallmarks of cancer pathogenesis. Overexpression of *SFRP4* in early-onset colon cancer and co-expression with EMT-linked genes provide an important first step towards understanding its molecular mechanism in young patients, particularly in the context of cancer metastasis and cell invasion.

**ARTICLE HIGHLIGHTS**

***Research background***

Colon cancer affects 1.2 million people around the world and causes about 0.6 million deaths annually. Although the overall incidence and mortality is decreasing, there has been an alarming increase in early-onset cases (< 50 years). These younger patients are often diagnosed at late stages with more aggressive tumors and tend to have poorer survival.

***Research motivation***

We previously showed that secreted frizzled-related protein 4 (*SFRP4*), speculated to play an essential role in cancer by inhibiting epithelial mesenchymal transition (EMT), is over-expressed in younger patients.

***Research objectives***

The aim of our study was to investigate whether there is a correlation between *SFRP4* expression and EMT-linked genes in colon cancer and whether *SFRP4* over-expression affects patient survival using a larger cohort of patients.

***Research methods***

Correlation between *SFRP4* expression and EMT-linked genes along with survival analysis were performed using the University of California Santa Cruz Cancer browser interface using publicly available The Cancer Genome Atlas-colon adenocarcinoma cohort of colon cancer cases.

***Research results***

*SFRP4* is co-expressed with EMT-linked markers, such as *CDH2*, *FN1*, *VIM*, *TWIST1*, *TWIST2*, *SNAI1*, *SNAI2*, *ZEB1*, *ZEB2*, *POSTN*, *MMP2*, *MMP7*, *MMP9*, and *COL1A1*, in colon cancer patients. *SFRP4* expression negatively correlated with the EMT-linked suppressors *CLDN4*, *CLDN7*, *TJP3*, *MUC1*, and *CDH1*. Mesenchymal-like samples showed higher expression of *SFRP4* and EMT-linked markers relative to epithelial-like samples. This implicates *SFRP4* in colon cancer EMT mechanism. Additionally, patients with colon tumors over-expressing *SFRP4* presented with significantly poorer overall survival.

***Research conclusions***

Results of this study suggest a potential role of *SFRP4* in colon cancer aggressiveness, disease progression, and poorer patient survival. Although the role of *SFRP*s including *SFRP4* as *WNT* signaling inhibitors is well documented in the literature, data presented in this manuscript suggest that the *SFRP* family proteins might also activate *WNT* signaling and promote cell proliferation, therefore demonstrating its oncogenic potential and suggesting its mechanism of action might be context dependent.

***Research perspectives***

More extensive and detailed mechanistic *in vitro* and *in vivo* studies will have to be performed to confirm these initial observations in colon cancer patients.

**ACKNOWLEDGEMENTS**

We would like to thank the patients without whom this work would not be possible.

**REFERENCES**

1 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

2 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

3 **American Cancer Society**. Key Statistics for Colorectal Cancer 2018. Available from: URL: https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html

4 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; **66**: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]

5 **Kirzin S**, Marisa L, Guimbaud R, De Reynies A, Legrain M, Laurent-Puig P, Cordelier P, Pradère B, Bonnet D, Meggetto F, Portier G, Brousset P, Selves J. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. *PLoS One* 2014; **9**: e103159 [PMID: 25083765 DOI: 10.1371/journal.pone.0103159]

6 **Davis DM**, Marcet JE, Frattini JC, Prather AD, Mateka JJ, Nfonsam VN. Is it time to lower the recommended screening age for colorectal cancer? *J Am Coll Surg* 2011; **213**: 352-361 [PMID: 21737316 DOI: 10.1016/j.jamcollsurg.2011.04.033]

7 **Bacani J**, Zwingerman R, Di Nicola N, Spencer S, Wegrynowski T, Mitchell K, Hay K, Redston M, Holowaty E, Huntsman D, Pollett A, Riddell R, Gallinger S. Tumor microsatellite instability in early onset gastric cancer. *J Mol Diagn* 2005; **7**: 465-477 [PMID: 16237216 DOI: 10.1016/S1525-1578(10)60577-6]

8 **Chang DT**, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. *Mod Pathol* 2012; **25**: 1128-1139 [PMID: 22481281 DOI: 10.1038/modpathol.2012.61]

9 **Giráldez MD**, Balaguer F, Bujanda L, Cuatrecasas M, Muñoz J, Alonso-Espinaco V, Larzabal M, Petit A, Gonzalo V, Ocaña T, Moreira L, Enríquez-Navascués JM, Boland CR, Goel A, Castells A, Castellví-Bel S. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. *Clin Cancer Res* 2010; **16**: 5402-5413 [PMID: 20924129 DOI: 10.1158/1078-0432.CCR-10-1491]

10 **Myers EA**, Feingold DL, Forde KA, Arnell T, Jang JH, Whelan RL. Colorectal cancer in patients under 50 years of age: a retrospective analysis of two institutions' experience. *World J Gastroenterol* 2013; **19**: 5651-5657 [PMID: 24039357 DOI: 10.3748/wjg.v19.i34.5651]

11 **Zahir MN**, Azhar EM, Rafiq S, Ghias K, Shabbir-Moosajee M. Clinical features and outcome of sporadic colorectal carcinoma in young patients: a cross-sectional analysis from a developing country. *ISRN Oncol* 2014; **2014**: 461570 [PMID: 25006505 DOI: 10.1155/2014/461570]

12 **Jandova J**, Xu W, Nfonsam V. Sporadic early-onset colon cancer expresses unique molecular features. *J Surg Res* 2016; **204**: 251-260 [PMID: 27451894 DOI: 10.1016/j.jss.2016.04.068]

13 **Ford CE**, Jary E, Ma SS, Nixdorf S, Heinzelmann-Schwarz VA, Ward RL. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells. *PLoS One* 2013; **8**: e54362 [PMID: 23326605 DOI: 10.1371/journal.pone.0054362]

14 **Kawano Y**, Kypta R. Secreted antagonists of the Wnt signalling pathway. *J Cell Sci* 2003; **116**: 2627-2634 [PMID: 12775774 DOI: 10.1242/jcs.00623]

15 **Kiper POS**, Saito H, Gori F, Unger S, Hesse E, Yamana K, Kiviranta R, Solban N, Liu J, Brommage R, Boduroglu K, Bonafé L, Campos-Xavier B, Dikoglu E, Eastell R, Gossiel F, Harshman K, Nishimura G, Girisha KM, Stevenson BJ, Takita H, Rivolta C, Superti-Furga A, Baron R. Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's Disease. *N Engl J Med* 2016; **374**: 2553-2562 [PMID: 27355534 DOI: 10.1056/NEJMoa1509342]

16 **Finger JH**, Smith CM, Hayamizu TF, McCright IJ, Xu J, Law M, Shaw DR, Baldarelli RM, Beal JS, Blodgett O, Campbell JW, Corbani LE, Lewis JR, Forthofer KL, Frost PJ, Giannatto SC, Hutchins LN, Miers DB, Motenko H, Stone KR, Eppig JT, Kadin JA, Richardson JE, Ringwald M. The mouse Gene Expression Database (GXD): 2017 update. *Nucleic Acids Res* 2017; **45**: D730-D736 [PMID: 27899677 DOI: 10.1093/nar/gkw1073]

17 **Chaffer CL**, Weinberg RA. A perspective on cancer cell metastasis. *Science* 2011; **331**: 1559-1564 [PMID: 21436443 DOI: 10.1126/science.1203543]

18 **Hay ED**. An overview of epithelio-mesenchymal transformation. *Acta Anat (Basel)* 1995; **154**: 8-20 [PMID: 8714286]

19 **Tomczak K**, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. *Contemp Oncol (Pozn)* 2015; **19**: A68-A77 [PMID: 25691825 DOI: 10.5114/wo.2014.47136]

20 **Nfonsam VN**, Nfonsam LE, Chen D, Omesiete PN, Cruz A, Runyan RB, Jandova J. COMP Gene Coexpresses With EMT Genes and Is Associated With Poor Survival in Colon Cancer Patients. *J Surg Res* 2019; **233**: 297-303 [PMID: 30502262 DOI: 10.1016/j.jss.2018.08.021.]

21 **Sanborn JZ**, Benz SC, Craft B, Szeto C, Kober KM, Meyer L, Vaske CJ, Goldman M, Smith KE, Kuhn RM, Karolchik D, Kent WJ, Stuart JM, Haussler D, Zhu J. The UCSC Cancer Genomics Browser: update 2011. *Nucleic Acids Res* 2011; **39**: D951-D959 [PMID: 21059681 DOI: 10.1093/nar/gkq1113]

22 **Cancer Genome Atlas Research Network**, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet* 2013; **45**: 1113-1120 [PMID: 24071849 DOI: 10.1038/ng.2764]

23 **Goldman M,** Craft B, Kamath A, Brooks AN, Zhu J, Haussler D. The UCSC Xena Platform for cancer genomics data visualization and interpretation. 2018 Preprint. Available from: bioRxiv:326470 [DOI: 10.1101/326470]

24 **Maganga R**, Giles N, Adcroft K, Unni A, Keeney D, Wood F, Fear M, Dharmarajan A. Secreted Frizzled related protein-4 (sFRP4) promotes epidermal differentiation and apoptosis. *Biochem Biophys Res Commun* 2008; **377**: 606-611 [PMID: 18938133 DOI: 10.1016/j.bbrc.2008.10.050]

25 **Muley A**, Majumder S, Kolluru GK, Parkinson S, Viola H, Hool L, Arfuso F, Ganss R, Dharmarajan A, Chatterjee S. Secreted frizzled-related protein 4: an angiogenesis inhibitor. *Am J Pathol* 2010; **176**: 1505-1516 [PMID: 20056841 DOI: 10.2353/ajpath.2010.090465]

26 **Eastham AM**, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL, Ward CM. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. *Cancer Res* 2007; **67**: 11254-11262 [PMID: 18056451 DOI: 10.1158/0008-5472.CAN-07-2253]

27 **Guarino M**, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. *Pathology* 2007; **39**: 305-318 [PMID: 17558857 DOI: 10.1080/00313020701329914]

28 **Vincent KM**, Postovit LM. Matricellular proteins in cancer: a focus on secreted Frizzled-related proteins. *J Cell Commun Signal* 2018; **12**: 103-112 [PMID: 28589318 DOI: 10.1007/s12079-017-0398-2]

29 **Vincent KM**, Postovit LM. A pan-cancer analysis of secreted Frizzled-related proteins: re-examining their proposed tumour suppressive function. *Sci Rep* 2017; **7**: 42719 [PMID: 28218291 DOI: 10.1038/srep42719]

30 **Finch PW**, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. *Proc Natl Acad Sci U S A* 1997; **94**: 6770-6775 [PMID: 9192640]

31 **Leyns L**, Bouwmeester T, Kim SH, Piccolo S, De Robertis EM. Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. *Cell* 1997; **88**: 747-756 [PMID: 9118218]

32 **Lin K**, Wang S, Julius MA, Kitajewski J, Moos M Jr, Luyten FP. The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling. *Proc Natl Acad Sci U S A* 1997; **94**: 11196-11200 [PMID: 9326585]

33 **Wang S**, Krinks M, Lin K, Luyten FP, Moos M Jr. Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. *Cell* 1997; **88**: 757-766 [PMID: 9118219]

34 **Mii Y**, Taira M. Secreted Frizzled-related proteins enhance the diffusion of Wnt ligands and expand their signalling range. *Development* 2009; **136**: 4083-4088 [PMID: 19906850 DOI: 10.1242/dev.032524]

35 **Bafico A**, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. *J Biol Chem* 1999; **274**: 16180-16187 [PMID: 10347172]

36 **Dann CE**, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ. Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. *Nature* 2001; **412**: 86-90 [PMID: 11452312 DOI: 10.1038/35083601]

37 **Rodriguez J**, Esteve P, Weinl C, Ruiz JM, Fermin Y, Trousse F, Dwivedy A, Holt C, Bovolenta P. SFRP1 regulates the growth of retinal ganglion cell axons through the Fz2 receptor. *Nat Neurosci* 2005; **8**: 1301-1309 [PMID: 16172602 DOI: 10.1038/nn1547]

38 **Yoshino K**, Rubin JS, Higinbotham KG, Uren A, Anest V, Plisov SY, Perantoni AO. Secreted Frizzled-related proteins can regulate metanephric development. *Mech Dev* 2001; **102**: 45-55 [PMID: 11287180]

39 **Bhat RA**, Stauffer B, Komm BS, Bodine PV. Structure-function analysis of secreted frizzled-related protein-1 for its Wnt antagonist function. *J Cell Biochem* 2007; **102**: 1519-1528 [PMID: 17471511 DOI: 10.1002/jcb.21372]

40 **Lee JL**, Lin CT, Chueh LL, Chang CJ. Autocrine/paracrine secreted Frizzled-related protein 2 induces cellular resistance to apoptosis: a possible mechanism of mammary tumorigenesis. *J Biol Chem* 2004; **279**: 14602-14609 [PMID: 14709558 DOI: 10.1074/jbc.M309008200]

41 **Smid M**, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. *Cancer Res* 2008; **68**: 3108-3114 [PMID: 18451135 DOI: 10.1158/0008-5472.CAN-07-5644]

42 **Saini S**, Liu J, Yamamura S, Majid S, Kawakami K, Hirata H, Dahiya R. Functional significance of secreted Frizzled-related protein 1 in metastatic renal cell carcinomas. *Cancer Res* 2009; **69**: 6815-6822 [PMID: 19723665 DOI: 10.1158/0008-5472.CAN-09-1254]

43 **Yamamura S**, Kawakami K, Hirata H, Ueno K, Saini S, Majid S, Dahiya R. Oncogenic functions of secreted Frizzled-related protein 2 in human renal cancer. *Mol Cancer Ther* 2010; **9**: 1680-1687 [PMID: 20501806 DOI: 10.1158/1535-7163.MCT-10-0012]

44 **von Marschall Z**, Fisher LW. Secreted Frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling. *Biochem Biophys Res Commun* 2010; **400**: 299-304 [PMID: 20723538 DOI: 10.1016/j.bbrc.2010.08.043]

45 **Kress E**, Rezza A, Nadjar J, Samarut J, Plateroti M. The frizzled-related sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine. *J Biol Chem* 2009; **284**: 1234-1241 [PMID: 19001373 DOI: 10.1074/jbc.M806548200]

46 **Halász K**, Kassner A, Mörgelin M, Heinegård D. COMP acts as a catalyst in collagen fibrillogenesis. *J Biol Chem* 2007; **282**: 31166-31173 [PMID: 17716974 DOI: 10.1074/jbc.M705735200]

47 **Clevers H**, Nusse R. Wnt/β-catenin signaling and disease. *Cell* 2012; **149**: 1192-1205 [PMID: 22682243 DOI: 10.1016/j.cell.2012.05.012]

48 **Steinhart Z**, Angers S. Wnt signaling in development and tissue homeostasis. *Development* 2018; **145** [PMID: 29884654 DOI: 10.1242/dev.146589]

49 **Yang Y**. Wnt signaling in development and disease. *Cell Biosci* 2012; **2**: 14 [PMID: 22520685 DOI: 10.1186/2045-3701-2-14]

**P-Reviewer:** Tarnawski AS, Kang GH **S-Editor:** Wang JL **L-Editor:** Filipodia **E-Editor:** Zhou BX

**Specialty type:** Oncology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 *SFRP4* co-expresses with epithelial mesenchymal transition-linked genes in colon cancer.** *SFRP4* and the epithelial mesenchymal transition-linked genes have higher expression in samples that are more mesenchymal (red) compared to the more epithelial samples with lower expression (blue).



**Figure 2 Epithelial mesenchymal transition-linked genes with positive correlation with *SFRP4* expression.**



**Figure 3 Epithelial mesenchymal transition-linked genes negative correlated with *SFRP4* expression.**



**Figure 4 Overall survival of colon cancer patients with low, intermediate, or high *SFRP4* expression.** A: Patients expressing higher levels of *SFRP4* (red line) had poor survival compared to those expressing lower *SFRP4* levels (blue line); (B) When a three group analysis was performed, patients with higher *SFRP4* expression (red line) presented with poor overall survival compared to patients with intermediate (white lines) or low expression (blue line).

**Table 1 Gender, age, and tumor stage of The Cancer Genome Atlas-colon adenocarcinoma dataset used for analysis**

|  |  |
| --- | --- |
|  | **Percentage** |
| Gender |
| Female | 46.8 |
| Male | 52.4 |
| Age of initial diagnosis |
| Average | 66.9 ± 13 |
| Minimum | 31 |
| maximum | 90 |
| Tumor stage |
| Stage I | 16.2 |
| Stage IA | 0.2 |
| Stage II | 6.5 |
| Stage IIA | 29.9 |
| Stage IIB | 2.2 |
| Stage IIC | 0.2 |
| Stage III | 4.3 |
| Stage IIIA | 1.7 |
| Stage IIIB | 12.8 |
| Stage IIIC | 8.9 |
| Stage IV | 10.0 |
| Stage IVA | 3.7 |
| Stage IVB | 0.4 |
| Not reported | 2.4 |
| Discrepant | 0.6 |